Press:

Nanoligent desarrolla nuevo fármaco anticanceroso. La Vanguardia

Nanoligent nova spin-off de la UAB i Hospital de Sant pau

Bibliography:

Mangues R, Vázquez E, Villaverde A. Targeting in cancer therapies. Medical Sciences 2016 vol: 4 (1)

Vazquez E, Unzueta U, Cespedes MV, Pesarrodona M, Rueda F, Zhikun X, Sanchez-Chardi A, Conchillo-Solé O, Serna N, Sánchez L, Daura X, Roldan M, Ferrer-Miralles N, Mangues R, Villaverde A. Designing protein nanoparticles to hit cancer cells. New biotechnology 2016 vol: 33 (25)

Vázquez E, Mangues R, Villaverde A. Functional recruitment for drug delivery through protein-based nanotechnologies. Nanomedicine (Lond). 2016; 11(11)1333-6.

Unzueta U, Céspedes MV, Vázquez E, Ferrer-Miralles N, Mangues R, Villaverde A. Toward protein-based viral mimetics for cancer therapies. Trends Biotechnol. 2015;33(5):253-8. 

Unzueta U, Céspedes MV, Ferrer-Miralles N, Casanova I, Cedano J, Corchero JL, Domingo-Espín J, Villaverde A, Mangues R, Vázquez E. Intracellular CXCR4⁺ cell targeting with T22-empowered protein-only nanoparticles. Int J Nanomedicine. 2012;7:4533-44.

Video: Metastasis